Common Contracts

2,734,375 Shares Repligen Corporation UNDERWRITING AGREEMENT

Underwriting Agreement • May 1st, 2019 • Repligen Corp • Biological products, (no disgnostic substances) • New York

• Contract Type
  Underwriting Agreement
• Filed
  May 1st, 2019
• Company
  Repligen Corp
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

Repligen Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A hereto (the “Underwriters”) an aggregate of 2,734,375 shares of its common stock, par value $0.01 per share (the “Common Stock”). The 2,734,375 shares of Common Stock to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 410,156 shares of Common Stock as provided in Section 2. The additional 410,156 shares of Common Stock to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” J.P. Morgan Securities LLC (“J.P. Morgan”) and Stephens Inc. have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sa

2,807,017 Shares Repligen Corporation UNDERWRITING AGREEMENT

Underwriting Agreement • June 29th, 2017 • Repligen Corp • Biological products, (no disgnostic substances) • New York

• Contract Type
  Underwriting Agreement
• Filed
  June 29th, 2017
• Company
  Repligen Corp
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

Repligen Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A hereto (the “Underwriters”) an aggregate of 2,807,017 shares of its common stock, par value $0.01 per share (the “Common Stock”). The 2,807,017 shares of Common Stock to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 421,052 shares of Common Stock as provided in Section 2. The additional 421,052 shares of Common Stock to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” J.P. Morgan Securities LLC (“J.P. Morgan”) and Stephens Inc. have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sa